Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority ...

The Mayo Clinic Center for Regenerative Biotherapeutics manufactures a wide range of products for active, early-phase clinical trials.

A digital therapeutics start-up which uses augmented reality (AR) glasses to aid people suffering from disorders including Parkinson's disease and multiple sclerosis will this week announce a £ ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

How Do I Get Tickets to Maná’s 2025-2026 Tour? Tickets for Maná’s “Vivir Sin Aire” are now on sale. Fans can also look for deals or get tickets to sold-out dates via StubHub, where your purchase is ...

STOCKHOLM, March 10, 2025 /CNW/ -- Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology, following the success of the SHINE ...

STOCKHOLM, March 10, 2025 /PRNewswire/ -- Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore® technology, following the success ...

About Checkpoint Therapeutics, Inc. Checkpoint is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments ...

A high throughput screen of >30,000 diverse repressor domains from across the tree of life identifies repressor domains with unique structures that underpin enhanced epigenetic effector domain ...

TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million ...